Next Article in Journal
Antibody Screening and Binding Prediction Analysis Targeting Stx2
Previous Article in Journal
Robustness Evaluation of a Legacy N-Glycan Profiling Method for a Therapeutic Antibody Under ICH Q14 Lifecycle Principles
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibodies
Volume 15
Issue 1
10.3390/antib15010010
antibodies-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antibodies as Tools for Characterization, Isolation and Production Enhancement of Anti-Cancer Drugs and Steroidal Hormones from Ginsenoside and Solasodine Glycoside: A Review

by
Yukihiro Shoyama
Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo 859-3298, Nagasaki, Japan
Antibodies 2026, 15(1), 10; https://doi.org/10.3390/antib15010010
Submission received: 27 September 2025 / Revised: 14 January 2026 / Accepted: 14 January 2026 / Published: 19 January 2026
(This article belongs to the Section Antibody Discovery and Engineering)
Browse Figures
Review Reports Versions Notes

Abstract

There are a vast number of monoclonal antibodies (MAbs) against biological components; however, the number for natural products is less than 50. MAbs against ginsenosides, i.e., dammarane triterpene glycosides contained in ginseng, were prepared to develop an Eastern blotting method that can estimate the number of bound sugars and pharmacological activity. Meanwhile, as a method for producing ginsenoside Rg3, which is used as an anti-cancer drug, an affinity column for ginsenoside Rb1 was prepared to isolate the raw material ginsenoside Rb1 in a single step, and a method for obtaining ginsenoside Rg3 through fermentation was proposed. A unique MAb capable of detecting all solasodine glycosides contained in Solanum plants was created to prepare an affinity column capable of isolating solasodine glycosides from S. khasianum fruit in a single step. The single-chain variable fragment gene was induced from the MAb against solasodine glycoside and introduced into the hairy root system of S. khasianum, thereby increasing the solasodine glycoside content more than twofold. As a result, we recognized that this method can be used to breed plants with higher concentrations of plant secondary metabolites like solasodine glycosides. The above results collectively demonstrate that solasodine glycoside can be isolated from S. khasianum in high yields and that this compound enables the production of steroids in high yields through a one-step chemical reaction.

1. Introduction

Since the dawn of human history, a vast number of plants have been used for medicinal purposes. Their uses can be roughly classified as follows: antibiotics [1], anti-cancer drugs [2], analgesics [3], immunosuppressants [4], heart disease treatments [5], and antimalaria drugs [6]. Therefore, approximately 50% of pharmaceuticals [7] are derived from natural sources, i.e., isolated or derived from plants, microorganisms, marine organisms, etc. Furthermore, many medicinal plants are also used in areas like traditional Chinese medicine, Kampo medicines, traditional Korean medicine, and Ayurveda.
For handling many types of medicinal plants, analytical methods for determining active ingredients and characteristic components are essential for maintaining a consistent quality of medicinal plants. The advent of thin-layer chromatography (TLC) and gas chromatography (GC) was followed by rapid developments in high-pressure liquid chromatography (HPLC) with MS (LC–MS) [8], LC–MS/MS [9], and UHPLC-QqQ-MS/MS [10], enabling high-sensitivity analysis. Monoclonal antibodies (MAbs) have been essential tools in biochemistry since the 1980s. MAbs were once limited to natural products such as morphine [11], but with the discovery of methods for determining the number of antigen molecules in haptens via MALDI-TOF MS [12], the number of MAbs has increased relative to the 1990s. The usefulness of MAbs against natural products has been recognized in a wide range of applications [13], including the confirmation of the activity of antigenic components in crude drugs, the evaluation of the quality of crude drugs and the in vivo dynamics of antigenic components, and the one-step isolation of antigenic components via an immunoaffinity column. Owing to their smallness, high tissue permeability, and the ease with which they can control blood concentrations, single-chain variable fragment (scFv) antibodies are being developed across a wide range of fields utilizing antibodies, including pharmaceuticals, particularly in cancer therapeutics and antibody–drug conjugates, diagnostics, sensors, and analytical kits [14]. However, the number of scFv antibodies targeting natural products is limited due to their restricted applications, as shown in Table 1 [15,16,17,18,19,20,21,22,23].
Panax ginseng C. A. Meyer is the most famous and important natural product with the name ginseng. It contains approximately 500 ginsenosides [24], as a major active constituent group, and polyacetylenes, sugars, amino acids, and alkaloids [25]. Ginseng has been well known since the Later Han period, and it has been used as an important drug in China. A total of 365 herbal medicines including animal- and mineral-derived crude drugs are listed in the Divine Farmer’s Classic of Materia Medica (100~200 AD) and are classified into three categories: highly safe (120 items), intermediate (120 items), and toxic (125 items). Ginseng, classified as highly safe, was said to have many mental benefits, such as healing the five organs, opening and calming the mind, stopping heart palpitations, eliminating evil spirits, enhancing cognition, and clarifying the eyes. Ginseng was introduced to Japan from China in the Nara period (710–794) during the reign of Shomu and has been included in the 60 Shosoin medicinal herbs.
In the early 1700s, a letter describing the natural habitat of ginseng in China was sent to Canada. Following expeditions made by Canadian people, American ginseng (P. quinquefolius Linne) was discovered, which was similar to the ginseng available in Canada in the 1710s. The overharvesting of wild species pushed it to the brink of extinction, but cultivation flourished in the 1800s. Today, approximately 1000 tons of dried American ginseng roots are produced and exported to China.
Tanshichi ginseng, P. notoginseng (Burk.) F.H. Chen, is a plant endemic to Yunnan Province in China. It was first discovered in the 16th century. The shape of the root is different from that of other Panax species (see Figure 1), and the medicinal properties described in the Honzo Tome [26] differ from those of ginseng; that is, it stops bleeding, disperses blood, and relieves pain.
Panax spp. have two types of structures, namely, protopanaxadiol-type ginsenoside Rb1 and protopanaxatriol-type ginsenoside Rg1, serving as major constituents, as indicated in Figure 2.
The aglycone formed when an OH group is attached to the C-6 position noted by the arrow is called the protopanaxatriol type. Protopanaxadiol-type and protopanaxatriol-type ginsenosides have different pharmacological effects. The former is known to have more powerful antitumor activity [27,28,29], while the latter is known to have strong anti-cognitive decline activity [30,31,32,33,34]. Protopanaxadiol-type ginsenosides have been reported to have strong antitumor activity; ginsenoside Rg3, which belongs to this category, is used in China as an anti-cancer agent, particularly as a metastasis prevention drug [35]. Ginsenoside Rd is also a protopanaxadiol-type ginsenoside like ginsenoside Rg3, indicating anti-cancer activity [36]. MAbs against ginsenosides such as ginsenoside Rb1 [37], ginsenoside Rg1 [38], ginsenoside Re [39], ginsenoside Rf [40], notoginsenoside R1 [41], ginsenoside Rg3 [42], ginsenoside Rh1, and ginsenoside Rg2 [43] have been prepared, and analytical methods using individual MAbs have been established. Alongside the advancement of antibody science, an MAb-staining method dubbed Eastern blotting [44] was established to determine pharmacological activity based on staining spots [45]. Fukuda et al. further prepared an affinity column loaded with an anti-ginsenoside Rb1 MAb and isolated ginsenoside Rb1 from ginseng extract in a single step [46]. The obtained ginsenoside Rb1 undergoes sequential cleavage of the C-20 sugar moiety through fermentation using Microbacterium spp. [47], yielding ginsenoside Rd and ginsenoside Rg3 in succession. Leveraging Solanum spp. in the family Solanaceae, which contains more than 2000 species, is the next task [48]. Among these species, S. khasianum C.B. Clarke is cultivated in India, China, Thailand, and other countries and used for medicinal purposes [49]. Solasodine glycosides are isolated from it and used for medicines, such as anti-inflammatory, anthelmintic [50], anti-diabetic [51], anti-acetylcholinesterase [52], anti-obesity, hepatoprotective, and anti-cancer drugs [53,54,55].
Pavani et al. reported the detection of steroidal alkaloids, flavonoids, phenols, tannins, steroids, and saponins in S. khasianum [56]. Mahato et al. isolated steroidal alkaloids such as solasonine, solamargine, and khasianine (Figure 3) from the fruit of S. khasianum and determined their structures via 13C NMR [57]. The antitumor activities of solasonine and solamargine have been confirmed using various cancer cell lines [58,59,60,61].
The structures of solasodine glycosides (Figure 3) and their pharmacological activities have been thoroughly studied, revealing their significance.
This review introduces methodologies using MAbs as an analytical tool, such as immunostaining (dubbed Eastern blotting) and a one-step purification method using an affinity column combined with MAbs specialized for the chemical structures of natural products like ginsenosides and solasodine glycosides. Furthermore, it describes a method for obtaining ginsenoside Rd and ginsenoside Rg3, which exhibit antitumor activity, through fermentation from ginsenoside Rb1 obtained from ginseng in a one-step process. For solasodine glycosides, we introduce the scFv gene for solamargine into S. khasianum cells to obtain plants with a high solasodine glycoside content. All solasodine glycosides are purified in a single step using an affinity column. We present a series of methods for obtaining steroid hormones from the resulting solasodine glycosides through chemical reactions.

2. Methods for Analyzing Natural Products Using MAbs

2.1. Eastern Blotting for Ginsenosides and Solasodine Glycosides

A unique technique named Eastern blotting, a type of immunoblotting, is used to analyze ginsenoside Rb1. Ginsenoside Rb1, separated via TLC from ginseng extract, is transferred onto a membrane, such as PVDF, via heating. The membrane is treated with NaIO4 solution, yielding aldehyde groups. BSA solution is added to induce conjugation between the sugar moiety and BSA. The membrane-bound ginsenoside Rb1 is then visualized using its MAb in a manner similar to Western blotting, as shown in Figure 4.
To stain ginsenosides via Eastern blotting, an anti-ginsenoside Rb1 MAb must be added to ginsenoside Rb1 immobilized on the membrane, as described above. The next step is to add labeled anti-IgG MAb followed by substrate to develop the color. Figure 5 shows the Eastern blotting analysis pathway for ginsenoside Rb1 [45].
Panel A in Figure 5 shows five ginsenoside standards developed via TLC and stained with H2SO4. All ginsenosides are stained. Meanwhile, panel B shows staining using Eastern blotting, where ginsenosides Rb1, Rc, and Rd are visible. These three ginsenosides belong to the protopanaxadiol category. This information demonstrates that using an MAb specific for protopanaxadiol-type ginsenosides allows for their detection [45]. Of course, protopanaxatriol-type ginsenosides Rg1 and Re can be stained using an anti-ginsenoside Rg1 MAb [45]. This can be performed by applying Eastern blotting to ginsenosides to assess their pharmacological activity. It is known that protopanaxadiol-type ginsenosides exhibit high antitumor activity [27,28,29] and anti-cognitive decline activity [30,31,32,33]. Additionally, double Eastern staining can be achieved by using both anti-ginsenoside Rb1 MAb and anti-ginsenoside Rg1 MAb, enabling the prediction of pharmacological activity for each spot [45]. Furthermore, from the Rf values in Figure 5, it can be inferred that the smaller the Rf value, the greater the number of sugar residues bound, depending on the type of sugar.
This section explains the Eastern blotting procedure for solasodine glycoside. The species S. khasianum primarily contains solasodine glycosides, though it also contains a few glycosides with other aglycones [57]. Furthermore, since the aim of this review was to synthesize steroid hormones from solasodine glycosides, the creation of an MAb with an affinity for all solasodine glycosides was required. Therefore, an MAb against solamargine was created, and it exhibited the broad affinity desired [62]. To investigate the characteristics of this MAb, we examined its cross-reactivity against various solasodine glycosides, yielding the following results: solamargine, 100%; solasonine, 92.1%; O-α-L-rhamnosyl-(1-2)-3-O-β-D-glucopyranosyl-solasodine, 36%; khasianine, 17%; and 3-O-β-D-glucopyranosyl-solasodine, 11% [62].
To visually demonstrate this unique property, evidence from Eastern blotting that had been performed on solasodine glycoside was employed, revealing very interesting results; specifically, all solasodine glycosides were stained, as shown in Figure 6 [63]. Based on this evidence, the antibody was found to be fully suitable for the analysis of all solasodine glycosides in this study.

2.2. Preparation of a Single-Chain Fv MAb Against Solamargine and Its Application

Putalun et al. developed recombinant antibody fragments, namely, scFv antibodies, against solamargine glycoside [20] derived from hybridoma cell lines [62]. The properties of the scFv protein expressed in E. coli were the same as those of the parent MAb [62]. It became evident that 220 ng of recombinant scFv was expressed in 1 mg of soluble protein of S. khasianum transgenic hairy root cultures obtained via infection. It is well known that Solanaceae plants possess a high capacity for redifferentiation from cells into plant bodies [64]. Therefore, when continuing the culturing of transgenic hairy roots, numerous hairy roots proliferated, underwent redifferentiation, and transitioned into plant bodies, as shown in Figure 7 [20]. Interestingly, there were 2.3-fold more solasodine glycosides, including solamargine, solasonine, and khasianine, in the transgenic hairy root than in the wild-type hairy root [20]. When the transgenic hairy roots were cultured in redifferentiation medium, redifferentiation occurred, leading to development into plant bodies that flowered and produced fruit. Since plant saponins are biosynthesized in phloem cells and stored in vacuoles [65,66], it is thought that the antigen–antibody reaction products—namely, the solasodine glycoside and scFv antibody complex, which may be an insoluble complex—are stored and accumulated in the vacuoles, resulting in approximately double the amount of solasodine glycoside biosynthesis. This fact provides important insights for plant breeding.
Regeneration from a transgenic hairy root occurred, yielding plantlets that grew into plants, bloomed, and bore fruit (see Figure 7). The concentration of solasodine glycoside in the fruits was about double that of the original plant [22]. The introduction of scFv genes into plant cells induces transformation, and plants with redifferentiation potential, like S. khasianum, can transform, making them applicable for breeding. As is well known, plant breeding involves cross-, mutation, polyploid, transgenic, genome-editing, and genomic breeding. The latest successful breeding method is a type of transgenic breeding. This novel method involves introducing scFv antibody genes and accordingly has been named “missile type molecule breeding.” [67]. Begum et al. collected many S. khasianum varieties and selected and bred varieties with high solasodine glycoside contents [68]. It may be possible to breed varieties with extremely high solasodine glycoside contents by infecting the good varieties selected in their study, i.e., those with high solasodine glycoside contents and transgenic hairy roots, and then re-differentiating the plants. The cited authors aimed to increase solasodine glycoside content, thereby improving the efficiency of steroid hormone production from solasodine glycosides. While prior research on plant-associated single-chain Fv antibodies successfully led to the creation of disease-resistant plants by introducing scFv targeting viral pathogens into host plants [69,70,71], this is the first example of applying scFv genes to breeding for low-molecular-weight natural products.

2.3. Purification via Immunoaffinity Column Conjugation of MAb for Ginsenosides and Solasodine Glycosides

The sugar chain of purified anti-ginsenoside MAb is oxidized and conjugated with hydrazide gel, yielding material for an immunoaffinity column. The crude extract of ginseng is charged to the immunoaffinity column and washed with phosphate buffer solution, yielding overcharged ginsenoside Rb1 and other components. After complete washing, ginsenoside Rb1 is eluted with AcOH buffer solution containing KSCN and MeOH to acquire pure ginsenoside Rb1(see Figure 8). The purity is confirmed via Eastern blotting, as discussed previously [46].
An immunoaffinity column for solasodine glycosides is prepared in the same way as in the case of ginsenoside Rb1. The S. khasianum fruit extract is loaded into an immunoaffinity column, washed with buffer solution, and then eluted with 40% MeOH in PBS solution to acquire the solasodine glycoside fraction, as confirmed by Eastern blotting using anti-solamargine Mab; as a result, only solamargine, solasonine, and khasianine are detected [72].
It has been clarified that only ginsenoside Rb1 or solasodine glycosides can be obtained in a single column using an immunoaffinity column, paving the way for the manufacture of the anti-cancer drugs ginsenoside Rd and Rg1 via fermentation and steroidal hormone preparations using the aglycone solasodine as a raw material.

3. Preparation of the Anti-Cancer Drugs Ginsenosides Rd and Rg3 from Ginsenoside Rb1 via Fermentation

Given that sugar chains cleave during steaming and/or fermentation, ginsenoside Rb1—which has long sugar chains and a high protopanaxadiol-type ginsenoside (the kind found in ginseng) content—was selected. As mentioned earlier, red ginseng contains ginsenosides, which are thought to be produced when one of the sugar chains is cleaved [73]. Unfortunately, quality control of red ginseng is considered difficult, so a different method must be selected. During fermentation, β-glucosidase secreted by lactic acid bacteria can hydrolyze major ginsenosides, such as ginsenosides Rb1 and Rg1, into minor ginsenosides, like Rg3, F2, and Rh2 [74,75]. Quan et al. isolated Microbacterium esteraromaticum from a sample from a ginseng farm. The 3β-glucosidase gene was cloned and expressed in E. coli. When ginsenoside Rb1 was incubated with the transgenic β-glucosidase, glucose at the C-20 position was cleaved in stages. That is, hydrolysis progressed from ginsenoside Rb1 to ginsenoside Rd and then ginsenoside Rg3 [47] as indicated in Figure 9. Ginsenoside Rd and Rg3 were purified from the fermented product via an affinity column loaded with ginsenoside Rg3 MAb [42].

4. Preparation of Steroid Hormone from Solasodine Glycosides

When synthesizing hormone agents using the natural product solasodine glycoside as a raw material, several steps are critical. 1. Solasodine glycoside must be obtained in a high yield. To achieve this, the scFv gene is introduced into S. khasianum plants to increase yield. 2. A method for rapidly isolating solasodine glycoside, which has a complex structural formula, must be developed. To achieve this, a unique immunoaffinity column must be created to develop a simplified isolation method. 3. Solasodine glycoside is hydrolyzed. 4. The resulting aglycone, solasodine, is converted into a steroid hormone via a chemical reaction. As outlined above, the raw material stage involves the use of MAb technology, and, ultimately, a one-step chemical reaction already under development is applied to produce the steroid hormone.
Figure 10 illustrates the step-wise conversion of solasodine into steroidal hormones. ZnCl2-AcOH causes the E and F rings of solasodine to open, producing an imine product; then, the double bond is cleaved to form a steroid structure, 16-dehydropregnenolone acetate [76].

5. Conclusions

A total of 500 ginsenosides were isolated from ginseng and structurally elucidated [24]. They are divided into protopanaxadiol- and protopanaxatriol-type ginsenosides based on their aglycones, and they have different pharmacological activities. Therefore, MAbs against ginsenoside Rb1 and ginsenoside Rg1 were prepared, and an Eastern blotting method that can pharmacologically distinguish ginsenosides was developed. Additionally, an affinity column using an MAb against ginsenoside Rb1 was prepared, enabling the isolation of ginsenoside Rb1 in a single step. This makes it possible to produce ginsenoside Rg3, which is used as an anti-cancer agent in China (see Figure 11), from ginsenoside Rb1 through β-glucosidase [35].
The anti-solamargine MAb recognizes all solasodine glycosides, so it was successfully used to prepare an immunoaffinity column that can separate specific solasodine glycosides. Additionally, an anti-solamargine scFv antibody gene [20] was employed as a breeding method to increase solasodine glycoside concentrations, and this gene was introduced into S. khasianum via infection using a hairy root system, yielding a method for increasing solasodine glycoside content, thus opening the way for steroid hormone production using the aglycone solasodine as a raw material. These results may significantly contribute to steroid hormone production.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data were taken from the references provided in the manuscript.

Acknowledgments

The authors sincerely thank the Faculty of Pharmacy, Nagasaki International University and the Association for Health Economics Research and Social Insurance and Welfare, for providing the facilities to support this project. The authors sincerely thank Hiroshi Yoshikawa for depicting the chemical structures.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Pérez-Flores, J.G.; García-Curiel, L.; Pérez-Escalante, E.; Contreras-López, E.; Aguilar-Lira, G.Y.; Ángel-Jijón, C.; González-Olivares, L.G.; Baena-Santillán, E.S.; Ocampo-Salinas, I.O.; Guerrero-Solano, J.A.; et al. Plant Antimicrobial Compounds and Their Mechanisms of Action on Spoilage and Pathogenic Bacteria: A Bibliometric Study and Literature Review. Appl. Sci. 2025, 15, 3516. [Google Scholar] [CrossRef]
  2. Lichota, A.; Gwozdzinski, K. Anticancer Activity of Natural Compounds from Plant and Marine Environment. Int. J. Mol. Sci. 2018, 19, 3533. [Google Scholar] [CrossRef]
  3. Rosendo, A.Y.; Filho, V.C.; Ferreira, J.; Calixto, J.B. The use of Natural Products as Sources of New Analgesic Drugs. Stud. Nat. Prod. Chem. 2005, 30, 191–212. [Google Scholar] [CrossRef]
  4. Nair, A.; Chattopadhyay, D.; Saha, B. Chapter 17. Plant-Derived Immunomodulators. In Advancements in Herbal Products as Novel Drug Leads; Academic Press: Cambridge, MA, USA, 2019; pp. 435–499. [Google Scholar] [CrossRef]
  5. Ray, S.; Saini, M.K. Cure and prevention of cardiovascular diseases: Herbs for heart. Clin. Phytosci. 2021, 7, 64. [Google Scholar] [CrossRef]
  6. Irungu, B.; Okari, E.; Nyangi, M.; Njeru, S.; Koech, L. Potential of medicinal plants as antimalarial agents: A review of work done at Kenya Medical Research Institute. Front. Pharmacol. 2023, 14, 1268924. [Google Scholar] [CrossRef] [PubMed]
  7. Veeresham, C. Natural products derived from plants as a source of drugs. J. Adv. Pharm. Technol. Res. 2012, 3, 200–201. [Google Scholar] [CrossRef]
  8. D’Urso, G.; Capuano, A.; Fantasma, F.; Chini, M.G.; Felice, V.D.; Saviano, G.; Lauro, G.; Casapullo, A.; Bifulco, G.; Iorizzi, M. The Role of LC-MS in Profiling Bioactive Compounds from Plant Waste for Cosmetic Applications: A General Overview. Plants 2025, 14, 2284. [Google Scholar] [CrossRef]
  9. Hoffmann, T.; Krug, D.; Hüttel, S.; Müller, R. Improving natural products identification through targeted LC-MS/MS in an untargeted secondary metabolomics work flow. Anal. Chem. 2014, 86, 10780–10788. [Google Scholar] [CrossRef]
  10. Wachełko, O.; Szpot, P.; Tusiewicz, K.; Nowak, K.; Chłopaś-Konowałek, A.; Zawadzki, M. An ultra-sensitive UHPLC-QqQ-MS/MS method for determination of 54 benzodiazepines (pharmaceutical drugs, NPS and metabolites) and z-drugs in biological samples. Talanta 2022, 251, 123816. [Google Scholar] [CrossRef]
  11. Jun-Ichi, S.; Noppavan, J.; Kunisuke, N.; Tadao, T. Production and characterization of high-affinity monoclonal antibodies against morphine. Mol. Immunol. 1988, 25, 937–943. [Google Scholar] [CrossRef]
  12. Shoyama, Y.; Fukada, T.; Tanaka, T.; Kusai, A.; Nojima, K. Direct determination of opium alkaloid-bovine serum albumin conjugate by matrix-assisted laser desorption/ionization mass spectrometry. Biol. Pharm. Bull. 1993, 16, 1051–1053. [Google Scholar] [CrossRef]
  13. Shoyama, Y. Studies on Natural Products Using Monoclonal Antibodies: A Review. Antibodies 2021, 10, 43. [Google Scholar] [CrossRef]
  14. Kussia, G.G.; Tessema, T.S. The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics. J. Immunol. Res. 2024, 2024, 1804038. [Google Scholar] [CrossRef]
  15. Yusakul, G.; Nuntawong, P.; Sakamoto, S.; Na Bhuket, P.R.; Kohno, T.; Kikkawa, N.; Rojsitthisak, P.; Shimizu, K.; Tanaka, H.; Morimoto, S. Bacterial Expression of a Single-Chain Variable Fragment (scFv) Antibody against Ganoderic Acid A: A Cost-Effective Approach for Quantitative Analysis Using the scFv-Based Enzyme-Linked Immunosorbent Assay. Biol. Pharm. Bull. 2017, 40, 1767–1774. [Google Scholar] [CrossRef]
  16. Paudel, M.K.; Takei, A.; Sakoda, J.; Juengwatanatrakul, T.; Sasaki-Tabata, K.; Putalun, W.; Shoyama, Y.; Tanaka, H.; Morimoto, S. Preparation of a Single-Chain Variable Fragment and a Recombinant Antigen-Binding Fragment against the Anti-Malarial Drugs, Artemisinin and Artesunate, and Their Application in an ELISA. Anal. Chem. 2012, 84, 2002–2008. [Google Scholar] [CrossRef]
  17. Yusakul, G.; Sakamoto, S.; Tanaka, H.; Morimoto, S. Efficient expression of single chain variable fragment antibody against paclitaxel using the Bombyx mori nucleopolyhedrovirus bacmid DNA system and its characterizations. J. Nat. Med. 2016, 70, 592–601. [Google Scholar] [CrossRef]
  18. Sakamoto, S.; Komatsu, S.; Moriyasu, A.; Yusakul, G.; Putalun, W.; Nuntawong, P.; Tanaka, H.; Morimoto, S. Single-chain variable fragment antibodies targeting the antileukemia agent harringtonine for enzyme-linked immunosorbent assay development. J. Immunoass. Immunochem. 2025, 46, 519–534. [Google Scholar] [CrossRef] [PubMed]
  19. Sakamoto, S.; Putalun, W.; Pongkitwitoon, B.; Juengwatanatrakul, T.; Shoyama, Y.; Tanaka, H.; Morimoto, S. Modulation of plumbagin production in Plumbago zeylanica using a single-chain variable fragment antibody against plumbagin. Plant Cell Rep. 2012, 31, 103–110. [Google Scholar] [CrossRef] [PubMed]
  20. Putalun, W.; Taura, F.; Qing, W.; Matsushita, H.; Tanaka, H.; Shoyama, Y. Single-chain Fv Antibody Stimulates Biosynthesis of Secondary Metabolites in Plants. Plant Cell Rep. 2002, 22, 344–349. [Google Scholar] [CrossRef] [PubMed]
  21. Matsukizono, M.; Kamegawa, M.; Tanaka, K.; Kohra, S.; Arizono, K.; Hamazoe, Y.; Sugimura, K. Characterization of a Single Chain Fv Antibody that Reacts with Free Morphine. Antibodies 2013, 2, 93–112. [Google Scholar] [CrossRef]
  22. Putalun, W.; Tanaka, H.; Sakamoto, S.; Shoyama, Y. Molecular Breeding of Solasodine Glycoside for Solanum khasianum using Anti-Solamargine Single-Chain Fv Gene. Med. Arom. Plants 2013, 2, 124. [Google Scholar] [CrossRef]
  23. Hammock, B.D. Biotinylated single-chain variable fragment-based enzyme-linked immunosorbent assay for glycocholic acid. Analyst 2018, 143, 2057–2065. [Google Scholar] [CrossRef]
  24. Fan, W.; Fan, L.; Wang, Z.; Mei, Y.; Liu, L.; Li, L.; Yang, L.; Wang, Z. Rare ginsenosides: A unique perspective of ginseng research. J. Adv. Res. 2024, 66, 303–328. [Google Scholar] [CrossRef] [PubMed]
  25. Ru, W.; Wang, D.; Xu, Y.; He, X.; Sun, Y.-E.; Qian, L.; Zhou, X.; Qin, Y. Chemical constituents and bioactivities of Panax ginseng (C. A. Mey.). Drug Discov. Ther. 2015, 9, 23–32. [Google Scholar] [CrossRef]
  26. Li, S. Compendium of Materia Medica; Beijing Ancient Books Press: Beijing, China, 1994; Volume 12, p. 334. [Google Scholar]
  27. Chen, X.-J.; Zhang, X.-J.; Shui, Y.-M.; Wan, J.-B.; Gao, J.-L. Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites. Evid.-Based Complement. Altern. Med. 2016, 2016, 5738694. [Google Scholar] [CrossRef] [PubMed]
  28. Lee, J.I.; Ha, Y.W.; Choi, T.W.; Kim, H.J.; Kim, S.-M.; Jang, H.-J.; Choi, J.-H.; Choi, M.H.; Chung, B.C.; Sethi, G.; et al. Cellular Uptake of Ginsenosides in Korean White Ginseng and Red Ginseng and Their Apoptotic Activities in Human Breast Cancer Cells. Planta Medica 2010, 77, 133–140. [Google Scholar] [CrossRef]
  29. Wang, C.-Z.; Anderson, S.; Du, W.; He, T.-C.; Yuan, C.-S. Red ginseng and cancer treatment. Chin. J. Nat. Med. 2016, 14, 7–16. [Google Scholar] [CrossRef] [PubMed]
  30. Lu, C.; Lv, J.; Dong, L.; Jiang, N.; Wang, Y.; Fan, B.; Wang, F.; Liu, X. Neuroprotective Effect of Ginsenoside Rh1 on Scopolamine-Induced Cognitive Dysfunctions. Neuropsychiatry 2018, 8, 749–760. [Google Scholar]
  31. Liang, H.-Y.; Zhang, P.-P.; Zhang, X.-L.; Zheng, Y.-Y.; Huang, Y.-R.; Zheng, G.-Q.; Lin, Y. Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease. Aging 2021, 13, 7549–7569. [Google Scholar] [CrossRef]
  32. Yang, Y.; Wang, L.; Zhang, C.; Guo, Y.; Li, J.; Wu, C.; Jiao, J.; Zheng, H. Ginsenoside Rg1 improves Alzheimer’s disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3β/β-catenin signaling pathway. Chem. Biol. Drug Des. 2022, 99, 884–896. [Google Scholar] [CrossRef]
  33. Quan, Q.; Ma, X.; Li, M.; Li, X.; Yuan, H. Ginsenoside Rg1 promotes β-amyloid peptide degradation through inhibition of the ERK/PPARγ phosphorylation pathway in an Alzheimer’s disease neuronal model. Exp. Ther. Med. 2023, 27, 31. [Google Scholar] [CrossRef] [PubMed]
  34. Shi, D.-D.; Huang, Y.-H.; Lai, C.S.W.; Dong, C.M.; Ho, L.C.; Li, X.-Y.; Wu, E.X.; Li, Q.; Wang, X.-M.; Chen, Y.-J.; et al. Ginsenoside Rg1 Prevents Chemotherapy-Induced Cognitive Impairment: Associations with Microglia-Mediated Cytokines, Neuroinflammation, and Neuroplasticity. Mol. Neurobiol. 2019, 56, 5626–5642. [Google Scholar] [CrossRef] [PubMed]
  35. Oh, H.-M.; Cho, C.-K.; Son, C.-G. Experimental Evidence for the Anti-Metastatic Action of Ginsenoside Rg3: A Systematic Review. Int. J. Mol. Sci. 2022, 23, 9077. [Google Scholar] [CrossRef]
  36. Li, J.; Huang, Q.; Yao, Y.; Ji, P.; Mingyao, E.; Chen, J.; Zhang, Z.; Qi, H.; Liu, J.; Chen, Z.; et al. Biotransformation, Pharmacokinetics, and Pharmacological Activities of Ginsenoside Rd Against Multiple Diseases. Front. Pharmacol. 2022, 13, 909363. [Google Scholar] [CrossRef] [PubMed]
  37. Tanaka, H.; Fukuda, N.; Shoyam, Y. Formation of monoclonal antibody against a major ginseng component, ginsenoside Rb1 and its characterization. Cytotechnology 1999, 29, 115–120. [Google Scholar] [CrossRef]
  38. Fukuda, N.; Tanaka, H.; Shoyama, Y. Formation of monoclonal antibody against a major ginseng component, ginsenoside Rg1 and its characterization. Monoclonal antibody for a ginseng saponin. Cytotechnology 2000, 34, 197–204. [Google Scholar] [CrossRef]
  39. Morinaga, O.; Tanaka, H.; Shoyama, Y. Detection and quantification of ginsenoside Re in ginseng samples by a chromatographic immunostaining method using monoclonal antibody against ginsenoside Re. J. Chromatogr. B 2006, 830, 100–104. [Google Scholar] [CrossRef]
  40. Nah, J.-J.; Song, J.-Y.; Choi, S.; Kim, S.-C.; Rhim, H.W.; Oh, T.H.; Lee, S.-M.; Nah, S.-Y. Preparation of Monoclonal Antibody against Ginsenoside Rf and Its Enzyme Immunoassay. Biol. Pharm. Bull. 2000, 23, 523–526. [Google Scholar] [CrossRef][Green Version]
  41. Limsuwanchote, S.; Wungsintaweekul, J.; Yusakul, G.; Han, J.-Y.; Sasaki-Tabata, K.; Tanaka, H.; Shoyama, Y.; Morimoto, S. Preparation of a Monoclonal Antibody against Notoginsenoside R1, a Distinctive Saponin from Panax notoginseng, and Its Application to Indirect Competitive ELISA. Planta Medica 2014, 80, 337–342. [Google Scholar] [CrossRef]
  42. Joo, E.J.; Ha, Y.W.; Shin, H.; Son, S.H.; Kim, Y.S. Generation and Characterization of Monoclonal Antibody to Ginsenoside Rg3. Biol. Pharm. Bull. 2009, 32, 548–552. [Google Scholar] [CrossRef][Green Version]
  43. Qu, H.; Wang, Y.; Shan, W.; Zhang, Y.; Feng, H.; Sai, J.; Wang, Q.; Zhao, Y. Development of ELISA for detection of Rh1 and Rg2 and potential method of immunoaffinity chromatography for separation of epimers. J. Chromatogr. B 2015, 985, 197–205. [Google Scholar] [CrossRef]
  44. Shan, S.; Tanaka, H.; Shoyama, Y. Enzyme-Linked Immunosorbent Assay for Glycyrrhizin Using Anti-Glycyrrhizin Monoclonal Antibody and an Eastern Blotting Technique for Glucuronides of Glycyrrhetic Acid. Anal. Chem. 2001, 73, 5784–5790. [Google Scholar] [CrossRef]
  45. Fukuda, N.; Tanaka, H.; Shoyama, Y. Applications of ELISA, Western blotting and immunoaffinity concentration for survey of ginsenosides in crude drugs of Panax species and traditional Chinese herbal medicines. Analyst 2000, 125, 1425–1429. [Google Scholar] [CrossRef] [PubMed]
  46. Fukuda, N.; Tanaka, H.; Shoyama, Y. Isolation of the Pharmacologically Active Saponin Ginsenoside Rb1 from Ginseng by Immunoaffinity Column Chromatography. J. Nat. Prod. 2000, 63, 283–285. [Google Scholar] [CrossRef] [PubMed]
  47. Quan, L.-H.; Min, J.-W.; Yang, D.-U.; Kim, Y.-J.; Yang, D.-C. Enzymatic biotransformation of ginsenoside Rb1 to 20(S)-Rg3 by recombinant β-glucosidase from Microbacterium esteraromaticum. Appl. Microbiol. Biotechnol. 2012, 94, 377–384. [Google Scholar] [CrossRef]
  48. Kaunda, J.S.; Zhang, Y.-J. The genus solanum: An ethnopharmacological, phytochemical and biological properties review. Nat. Prod. Bioprospect. 2019, 9, 77–137. [Google Scholar] [CrossRef]
  49. Gogoi, R.; Sarma, N.; Pandey, S.K.; Lal, M. Phytochemical constituents and pharmacological potential of Solanum khasianum C.B. Clarke., extracts: Special emphasis on its skin whitening, anti-diabetic, acetylcholinesterase and genotoxic activities. Trends Phytochem. Res. 2021, 5, 47–61. [Google Scholar]
  50. Jarald, E.E.; Edwin, S.; Saini, V.; Deb, L.; Gupta, V.B.; Wate, S.P.; Busari, K.P. Anti-inflammatory and anthelmintic activities of Solanum khasianum Clarke. Nat. Prod. Res. 2008, 22, 269–274. [Google Scholar] [CrossRef]
  51. Chirumamilla, P.; Taduri, S. Assessment of in vitro anti-inflammatory, antioxidant and antidiabetic activities of Solanum khasianum Clarke. Vegetos 2023, 36, 575–582. [Google Scholar] [CrossRef]
  52. Kumar, R.; Khan, M.I.; Prasad, M. Badruddeen Solasodine: A Perspective on their roles in Health and Disease. Res. J. Pharm. Technol. 2019, 12, 2571–2576. [Google Scholar] [CrossRef]
  53. Daunter, B.; Cham, B. Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Lett. 1990, 55, 209–220. [Google Scholar] [CrossRef]
  54. Hameeda, A.; Ijaza, S.; Mohammadb, I.S.; Muhammadc, K.S.; Akhtara, N.; Khana, H.M.S. Aglycone solanidine and solasodine derivatives: A natural approach towards cancer. Biomed. Pharmacother. 2017, 94, 446–457. [Google Scholar] [CrossRef]
  55. Zhuang, Y.; Wu, C.; Zhou, J.; Chen, X.; Wu, J.; Jiang, S.; Peng, H.; Zou, X.; Liu, J.; Wu, D.; et al. Solasodine inhibits human colorectal cancer cells through suppression of the AKT/glycogen synthase kinase-3β/β-catenin pathway. Cancer Sci. 2017, 108, 2248–2264. [Google Scholar] [CrossRef]
  56. Pavani, C.; Shasthree, T. Qualitative screening and Quantitative determination of secondary metabolites from different plant extracts of Solanum khasianum Clarke. Res. J. Chem. Environ. 2022, 26, 113–123. [Google Scholar] [CrossRef]
  57. Mahato, S.B.; Sahu, N.P.; Ganguly, A.N.; Kasai, R.; Tanaka, O. Steroidal alkaloids from Solanum khasianum: Application of 13C NMR spectroscopy to their structural elucidation. Phytochemistry 1980, 19, 2017–2020. [Google Scholar] [CrossRef]
  58. Wang, Y.; Wang, T.; Liu, W.; Luo, G.; Lu, G.; Zhang, Y.; Wang, H. Anticancer effects of solasonine: Evidence and possible mechanisms. Biomed. Pharmacother. 2024, 171, 116146. [Google Scholar] [CrossRef] [PubMed]
  59. Munari, C.C.; de Oliveira, P.F.; Campos, J.C.L.; Martins, S.d.P.L.; Da Costa, J.C.; Bastos, J.K.; Tavares, D.C. Antiproliferative activity of Solanum lycocarpum alkaloidic extract and their constituents, solamargine and solasonine, in tumor cell lines. J. Nat. Med. 2013, 68, 236–241. [Google Scholar] [CrossRef] [PubMed]
  60. Zhang, H.; Lv, J.-L.; Zheng, Q.-S.; Li, J. Active components of Solanum nigrum and their antitumor effects: A literature review. Front. Oncol. 2023, 13, 1329957. [Google Scholar] [CrossRef]
  61. Lan, X.; Lu, M.; Fang, X.; Cao, Y.; Sun, M.; Shan, M.; Gao, W.; Wang, Y.; Yu, W.; Luo, H. Anti-Colorectal Cancer Activity of Solasonin from Solanum nigrum L. via Histone Deacetylases-Mediated p53 Acetylation Pathway. Molecules 2023, 28, 6649. [Google Scholar] [CrossRef] [PubMed]
  62. Ishiyama, M.; Shoyama, Y.; Murakami, H.; Shinohara, H. Production of monoclonal antibodies and development of an ELISA for solamargine. Cytotechnology 1996, 18, 153–158. [Google Scholar] [CrossRef]
  63. Putalun, W.; Tanaka, H.; Yahara, S.; Lhieochaiphan, S.; Shoyama, Y. Survey of Solasodine-Type Glycoalkaloids by Western Blotting and ELISA Using Anti-solamargine Monoclonal Antibody. Biol. Pharm. Bull. 2000, 23, 72–75. [Google Scholar] [CrossRef][Green Version]
  64. Ohnuma, M.; Teramura, H.; Shimada, H. A simple method to establish an efficient medium suitable for potato regeneration. Plant Biotechnol. 2020, 37, 25–30. [Google Scholar] [CrossRef]
  65. Faizal, A.; Geelen, D. Saponins and their role in biological processes in plants. Phytochem. Rev. 2013, 12, 877–893. [Google Scholar] [CrossRef]
  66. Francisco, R.d.B.; Martinoia, E. The Vacuolar Transportome of Plant Specialized Metabolites. Plant Cell Physiol. 2018, 59, 1326–1336. [Google Scholar] [CrossRef] [PubMed]
  67. Putalun, W. Technology of Compact MAb and its Application for Medicinal Plant Breeding Named as Missile Type Molecular Breeding. Curr. Cancer Drug Targets 2011, 8, 24–31. [Google Scholar] [CrossRef]
  68. Begum, T.; Munda, S.; Gupta, T.; Gogoi, R.; Choubey, V.K.; Chanda, S.K.; Lekhak, H.; Sastry, G.N.; Lal, M. Stability estimation through multivariate approach among solasodine-rich lines of Solanum khasianum (C.B. Clarke): An important industrial plant. Front. Plant Sci. 2023, 14, 1143778. [Google Scholar] [CrossRef] [PubMed]
  69. Fecker, L.F.; Kaufmann, A.; Commandeur, U.; Commandeur, J.; Koenig, R.; Burgermeister, W. Expression of single-chain antibody fragments (scFv) specific for beet necrotic yellow vein virus coat protein or 25 kDa protein in Escherichia coli and Nicotiana benthamiana. Plant Mol. Biol. 1996, 32, 979–986. [Google Scholar] [CrossRef]
  70. Fecker, L.F.; Koenig, R.; Obermeier, C. Nicotiana benthamiana plants expressing beet necrotic yellowvein virus (BNYVV) coat protein-specific scFv are partiallyprotected against the establishment of the virus in the early stages of infection and its pathogenic effectsin the late stages of infection. Arch. Virol. 1997, 142, 1857–1863. [Google Scholar] [CrossRef]
  71. Satheeshkumar, P.K. Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A Comprehensive Update. Mol. Biotechnol. 2020, 62, 151–167. [Google Scholar] [CrossRef]
  72. Putalun, W.; Tanaka, H.; Shoyama, Y. Rapid separation of solasodine glycosides by an immunoaffinity column using anti-solamargine monoclonal antibody. Cytotechnology 1999, 31, 153–158. [Google Scholar] [CrossRef]
  73. Kitagawa, I.; Taniyama, T.; Shibuya, H.; Noda, T.; Yoshikawa, M. Chemical Studies on Crude Drug Processing. V. On the Constituents of Ginseng Radix Rubra (2): Comparison of the Constituents of White Ginseng and Red Ginseng Prepared from the Same Panax ginseng Root. Yakugaku Zasshi 1987, 107, 495–505. [Google Scholar] [CrossRef] [PubMed]
  74. Liu, S.; Liu, S.; Mi, Q.; Yin, P.; Xue, T.; Yu, X.; Meng, X.; Wang, L.; Bi, Y. Changes in Active Components and Antioxidant Properties of Ginseng Fermented by Lactobacillus plantarum. Food Sci. 2023, 44, 252–259. [Google Scholar]
  75. Lee, H.Y.; Lee, J.H.; Shin, E.-C.; Cho, D.Y.; Jung, J.G.; Kim, M.J.; Bin Jeong, J.; Kang, D.; Kang, S.S.; Cho, K.M. Changes in Chemical Compositions and Antioxidant Activities from Fresh to Fermented Red Mountain-Cultivated Ginseng. Molecules 2022, 27, 4550. [Google Scholar] [CrossRef] [PubMed]
  76. Vronen, P.J.E. Potato Glycoalkaloids as Starting Material for the Synthesis of Steroid Hormones. Doctoral Dissertation, Wageningen University, Wageningen, The Netherlands; pp. 77–78.
Antibodies 15 00010 g001
Figure 1. The shapes of ginseng roots: American ginseng (left) and Tanshichi ginseng (right) (photo by Y. Shoyama).
Figure 1. The shapes of ginseng roots: American ginseng (left) and Tanshichi ginseng (right) (photo by Y. Shoyama).
Antibodies 15 00010 g001
Antibodies 15 00010 g002
Figure 2. Structures of the major ginsenosides, ginsenoside Rb1 and ginsenoside Rg1, in Panax spp.; Arrow shows C-6 position.
Figure 2. Structures of the major ginsenosides, ginsenoside Rb1 and ginsenoside Rg1, in Panax spp.; Arrow shows C-6 position.
Antibodies 15 00010 g002
Antibodies 15 00010 g003
Figure 3. Structures of solasodine and its glycosides, khasianine, solamargine, and solasonine, contained in Solanum khasianum.
Figure 3. Structures of solasodine and its glycosides, khasianine, solamargine, and solasonine, contained in Solanum khasianum.
Antibodies 15 00010 g003
Antibodies 15 00010 g004
Figure 4. Scheme of using Eastern blotting to analyze ginsenoside Rb1.
Figure 4. Scheme of using Eastern blotting to analyze ginsenoside Rb1.
Antibodies 15 00010 g004
Antibodies 15 00010 g005
Figure 5. Eastern blotting profile of ginsenosides analyzed using anti-ginsenoside Rb1 Mab.
Figure 5. Eastern blotting profile of ginsenosides analyzed using anti-ginsenoside Rb1 Mab.
Antibodies 15 00010 g005
Antibodies 15 00010 g006
Figure 6. Easten blotting of solasodine glycosides using an anti-solamargine Mab. 1: Solamargine; 2: solasonine; 3: khasianine; 4: 3-O-β-D-glucopyranosyl solasodine; 5: O-α-L-rhamnosyl-(1-2)-3-O-β-D-glucopyranosyl solasodine; 6: 3-O-β-D-galactopyranosyl solasodine; 7: O-β-D-glucopyranosyl-(1-3)-3-O-β-D-galactopyranosyl solasodine; 8: solaverine I; 9: solaverine II; 10: 12-hydroxysolamargine; 11: 12-hydroxysolasonine.
Figure 6. Easten blotting of solasodine glycosides using an anti-solamargine Mab. 1: Solamargine; 2: solasonine; 3: khasianine; 4: 3-O-β-D-glucopyranosyl solasodine; 5: O-α-L-rhamnosyl-(1-2)-3-O-β-D-glucopyranosyl solasodine; 6: 3-O-β-D-galactopyranosyl solasodine; 7: O-β-D-glucopyranosyl-(1-3)-3-O-β-D-galactopyranosyl solasodine; 8: solaverine I; 9: solaverine II; 10: 12-hydroxysolamargine; 11: 12-hydroxysolasonine.
Antibodies 15 00010 g006
Antibodies 15 00010 g007
Figure 7. Preparation of scFv gene against solamargine and its use for increasing solasodine glycoside content in S. khasianum.
Figure 7. Preparation of scFv gene against solamargine and its use for increasing solasodine glycoside content in S. khasianum.
Antibodies 15 00010 g007
Antibodies 15 00010 g008
Figure 8. One-step purification of ginsenoside Rb1 using an immunoaffinity column combined with anti-ginsenoside Rb1 Mab.
Figure 8. One-step purification of ginsenoside Rb1 using an immunoaffinity column combined with anti-ginsenoside Rb1 Mab.
Antibodies 15 00010 g008
Antibodies 15 00010 g009
Figure 9. Production of the anti-cancer drugs ginsenoside Rd and Rg3 from ginsenoside Rb1.
Figure 9. Production of the anti-cancer drugs ginsenoside Rd and Rg3 from ginsenoside Rb1.
Antibodies 15 00010 g009
Antibodies 15 00010 g010
Figure 10. Preparation of steroid hormones from solasodine glycosides via a chemical reaction.
Figure 10. Preparation of steroid hormones from solasodine glycosides via a chemical reaction.
Antibodies 15 00010 g010
Antibodies 15 00010 g011
Figure 11. The anti-cancer drug ginsenoside Rg3 (photo by Y. Shoyama).
Figure 11. The anti-cancer drug ginsenoside Rg3 (photo by Y. Shoyama).
Antibodies 15 00010 g011
Table 1. Preparation of single-chain Fv antibodies against natural products.
Table 1. Preparation of single-chain Fv antibodies against natural products.
Plant ComponentPlant ResourceReference
Ganoderic acidGanoderma lucidum[15]
ArtemisininArtemisia annua[16]
PaclitaxelTaxus brevifolia[17]
HarringtonineCephalotaxus harringtonii[18]
PlumbaginPlumbago zeylanica[19]
SolamargineSolanum khasianum[20,22]
MorphinePapaver somuniterum[21]
Glycocholic acid(Bile; animal)[23]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Shoyama, Y. Antibodies as Tools for Characterization, Isolation and Production Enhancement of Anti-Cancer Drugs and Steroidal Hormones from Ginsenoside and Solasodine Glycoside: A Review. Antibodies 2026, 15, 10. https://doi.org/10.3390/antib15010010

AMA Style

Shoyama Y. Antibodies as Tools for Characterization, Isolation and Production Enhancement of Anti-Cancer Drugs and Steroidal Hormones from Ginsenoside and Solasodine Glycoside: A Review. Antibodies. 2026; 15(1):10. https://doi.org/10.3390/antib15010010

Chicago/Turabian Style

Shoyama, Yukihiro. 2026. "Antibodies as Tools for Characterization, Isolation and Production Enhancement of Anti-Cancer Drugs and Steroidal Hormones from Ginsenoside and Solasodine Glycoside: A Review" Antibodies 15, no. 1: 10. https://doi.org/10.3390/antib15010010

APA Style

Shoyama, Y. (2026). Antibodies as Tools for Characterization, Isolation and Production Enhancement of Anti-Cancer Drugs and Steroidal Hormones from Ginsenoside and Solasodine Glycoside: A Review. Antibodies, 15(1), 10. https://doi.org/10.3390/antib15010010

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop